Cancer · 2021 · 32 citations · 25 references
MedicineMolecular GeneticsMedical GeneticsMolecular OncologyPediatric GeneticsBone Marrow PathologyGenetic DisordersGenetic SyndromesMyelodysplastic SyndromesClinicopathological CorrelationPrognostic CriteriaRevised International Prognostic Scoring SystemSf3b1 Mutation
Background SF3B1 mutations ( SF3B1 mut ) in myelodysplastic syndromes (MDS) frequently involve codon K700E and have a favorable prognosis. The prognostic effect of non‐K700E SF3B1 mut is uncertain. Methods The authors analyzed the clinicopathological features and outcomes of a single‐institution series of 94 treatment‐naive SF3B1 mut MDS patients (18%) and 415 treatment‐naive SF3B1 wt MDS patients and explored the differences between K700E and non‐K700E SF3B1 mut MDS. Results Fifty‐five patients (59%) carried K700E. Recurrent non‐K700E mutations (39 [41%]) included R625, H662, and K666. Compared with SF3B1 mut K700E patients, non‐K700E patients had a lower median absolute neutrophil count (1.8 vs 2.4; P = .005) and were frequently “high” according to the Revised International Prognostic Scoring System (19% vs 4%; P = .031). Non‐K700E MDS was associated frequently with RUNX1 (26% vs 7%; P = .012) and exclusively with BCOR , IDH2 , and SRSF2 mutations. A splicing analysis showed the differential distribution of alternatively spliced events and gene expression profiles between K700 and non‐K700E MDS patients. The majority (at least 80%) of SF3B1 mut K700E, SF3B1 mut non‐K700E, and SF3B1 wt patients were treated with hypomethylating agents. Over a median follow‐up of 16 months, SF3B1 mut had superior overall survival (OS) in comparison with SF3B1 wt in all MDS patients (not reached vs 25.2 months; P = .0003), in patients with low‐grade MDS, and in patients with myelodysplastic syndromes with ring sideroblasts (MDS‐RS). Compared with SF3B1 wt , SF3B1 mut K700E had superior outcomes in all MDS (median OS, 25 months vs not reached; P = .0001), in low‐grade MDS (median OS, 41.3 months vs not reached; P = .0015), and in MDS‐RS (median OS, 22.3 months vs not reached; P = .0001), but no significant difference was seen between non‐K700E and SF3B1 wt MDS. By multivariable analysis, the absence of SF3B1 mut K700E mutations was independently associated with the prognosis. Conclusions This study highlights the importance of the SF3B1 mutation subtype in MDS risk assessment. Lay Summary Myelodysplastic syndromes (MDS) with SF3B1 mutations are regarded as having a favorable prognosis by both the World Health Organization and the International Working Group for the Prognosis of Myelodysplastic Syndromes. However, this article shows that only MDS patients with SF3B1 K700E mutations have a favorable prognosis (and not MDS patients with SF3B1 mutations involving other codons). This has important implications for refining future MDS subclassification and risk assessment criteria.
25
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida, Masashi Sanada, Yuichi Shiraishi et al. · Nature · 2011 · 2.1K citations
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati et al. · Blood · 2013 · 1.8K citations